Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

855 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of 5-fluorouracil-leucovorin plus bevacizumab for chemotherapy-naïve older or frail patients with metastatic colorectal cancer (OGSG 0802).
Ohta T, Kato T, Kawakami H, Miyake Y, Goto M, Iwamoto S, Otsuji T, Nakamura M, Sugimoto N, Okamura S, Kotaka M, Tsujie M, Tokunaga Y, Mishima H, Hata T, Shimokawa T, Kurokawa Y, Satoh T. Ohta T, et al. Among authors: iwamoto s. Int J Clin Oncol. 2020 Jul;25(7):1291-1298. doi: 10.1007/s10147-020-01656-3. Epub 2020 Mar 26. Int J Clin Oncol. 2020. PMID: 32219630 Clinical Trial.
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Oki E, Kato T, Bando H, Yoshino T, Muro K, Taniguchi H, Kagawa Y, Yamazaki K, Yamaguchi T, Tsuji A, Iwamoto S, Nakayama G, Emi Y, Touyama T, Nakamura M, Kotaka M, Sakisaka H, Yamanaka T, Kanazawa A. Oki E, et al. Among authors: iwamoto s. Clin Colorectal Cancer. 2018 Jun;17(2):147-155. doi: 10.1016/j.clcc.2018.01.011. Epub 2018 Feb 9. Clin Colorectal Cancer. 2018. PMID: 29530335 Free article. Clinical Trial.
Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Kotaka M, Iwamoto S, Satake H, Sakai D, Kudo T, Fukunaga M, Konishi K, Ide Y, Ikumoto T, Tsuji A, Sano Y, Kato T, Sugimoto N, Satoh T, Kanazawa A, Kurata T, Yamanaka T, Tomita N. Kotaka M, et al. Among authors: iwamoto s. Int J Clin Oncol. 2020 Aug;25(8):1515-1522. doi: 10.1007/s10147-020-01701-1. Epub 2020 May 14. Int J Clin Oncol. 2020. PMID: 32409917 Clinical Trial.
Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y, Takahari D, Matsumoto H, Baba H, Nakamura M, Yoshida K, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Yamada Y, et al. Among authors: iwamoto s. Lancet Oncol. 2013 Dec;14(13):1278-86. doi: 10.1016/S1470-2045(13)70490-X. Epub 2013 Nov 11. Lancet Oncol. 2013. PMID: 24225157 Clinical Trial.
FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study.
Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. Iwamoto S, et al. Ann Oncol. 2015 Jul;26(7):1427-33. doi: 10.1093/annonc/mdv197. Epub 2015 Apr 23. Ann Oncol. 2015. PMID: 25908603 Free PMC article. Clinical Trial.
S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT study.
Baba H, Yamada Y, Takahari D, Matsumoto H, Yoshida K, Nakamura M, Yoshida M, Iwamoto S, Shimada K, Komatsu Y, Sasaki Y, Satoh T, Takahashi K, Mishima H, Muro K, Watanabe M, Sakata Y, Morita S, Shimada Y, Sugihara K. Baba H, et al. Among authors: iwamoto s. ESMO Open. 2017 Mar 9;2(1):e000135. doi: 10.1136/esmoopen-2016-000135. eCollection 2017. ESMO Open. 2017. PMID: 28761727 Free PMC article.
A prospective Phase II study to examine the relationship between quality of life and adverse events of first-line chemotherapy plus cetuximab in patients with KRAS wild-type unresectable metastatic colorectal cancer: QUACK trial.
Iwamoto S, Ooki A, Morita S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Sudo T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Iwamoto S, et al. Cancer Med. 2018 Sep;7(9):4217-4227. doi: 10.1002/cam4.1623. Epub 2018 Jul 26. Cancer Med. 2018. PMID: 30051609 Free PMC article. Clinical Trial.
Patient-reported symptom burden as a prognostic factor in treatment with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A, Morita S, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Sakamoto J, Tsuji A, Ando M, Yamaguchi K. Ooki A, et al. Among authors: iwamoto s. Cancer Med. 2020 Mar;9(5):1779-1789. doi: 10.1002/cam4.2826. Epub 2020 Jan 21. Cancer Med. 2020. PMID: 31962002 Free PMC article. Clinical Trial.
Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial.
Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K. Ooki A, et al. Among authors: iwamoto s. Cancer Med. 2020 Dec;9(24):9419-9430. doi: 10.1002/cam4.3564. Epub 2020 Nov 21. Cancer Med. 2020. PMID: 33222406 Free PMC article. Clinical Trial.
855 results